Nektar Therapeutics vs Zymeworks
NKTR and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NKTR and ZYME compare
Zymeworks is the larger company, worth 1.5 times as much as Nektar Therapeutics ($1.9B against $1.2B).
Nektar Therapeutics grew revenue faster over the last twelve months (−43.9% versus −69.8% for Zymeworks).
Nektar Therapeutics keeps more of each dollar of sales as profit, with a net margin of −297% compared with −404% at Zymeworks.
Nektar Therapeutics scores higher on the StockData Score (9 against 5 for Zymeworks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NKTR | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $1.9B |
| Share price | $36.44 | $26.45 |
| Change, 1 year | −32.5% | 43.0% |
| Change, 5 years | −78.3% | 35.6% |
| Beta (5Y) | 0.63 | 0.28 |
| Employees | 63 | 264 |
| StockData Score | ||
| Total score | 9 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 22.5× (better) | 50.6× |
| P/B | 1.4× (better) | 23.4× |
| FCF yield | −16.8% | −6.4% (better) |
| Fair value | – | $3.39 |
| Margin of safety | – | −680% |
| Growth | ||
| Revenue growth (TTM) | −43.9% (better) | −69.8% |
| Revenue growth, 5Y average | −18.4% | 22.2% (better) |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −254% (better) | −419% |
| Net margin | −297% (better) | −404% |
| FCF margin | −378% | −325% (better) |
| Return on equity | −37.3% (better) | −72.3% |
| Return on invested capital | −1186% | −179% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.42 (better) | 6.32 |
| Altman Z-score | −0.67 (better) | −1.01 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | 9.0% (better) |
| Shareholder yield | 0.00% | 9.0% (better) |
| Ownership | ||
| Held by institutions | 105% | 98.1% |
| Held by insiders | 0.46% | 58.9% |
| Insider net buying, 12 months | −$2.2M (better) | −$5.0M |
| Short interest, % of float | 19.9% | 20.3% |
Go deeper
- NKTR stock overview
- NKTR income statement
- NKTR valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.